TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21557525

Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg plus MTX
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Rituximab 1,000 mg plus MTX
Number of subjects: 748

Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Rituximab plus MTX (both doses)
Number of subjects: 748
Study: 19490279

Group type: EXPERIMENTAL
Intervention: Telephone Support System (TSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internet Support (WEB)
Number of subjects: 0
Study: 16741262

Group type: EXPERIMENTAL
Intervention: Arginine (7 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arginine + Exercise (Arg+Ex)
Number of subjects: 8
Study: 14734396

Group type: EXPERIMENTAL
Intervention: Triage and transportation to MIU by ambulance crews
Number of subjects: 344

Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 344
Study: 10945489

Group type: EXPERIMENTAL
Intervention: Gemcitabine + BSC
Number of subjects: 300

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 300
Study: 9128274

Group type: EXPERIMENTAL
Intervention: Cell Hemoglobin Distribution Width (CHDW) < 3.05
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CHDW/RBC ratio of 0.57
Number of subjects: 0
Study: 8404805

Group type: EXPERIMENTAL
Intervention: Contingency-planning exercise
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Enhancing attitude-behavior correspondence (handling condoms)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 291
Study: 3544622

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metoprolol (200 mg/day)
Number of subjects: 24
Study: 28332301

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 87
Study: 25174679

Group type: EXPERIMENTAL
Intervention: Anthelminthic drug administration
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: FLOTAC technique
Number of subjects: 115

Group type: COMPARATOR
Intervention: Kato-Katz technique
Number of subjects: 115
Study: 22836602

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion (vodka and orange juice; ALC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (caloric and taste‐matched nonalcoholic beverage; CONT)
Number of subjects: 9
Study: 21493741

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 18637983

Group type: EXPERIMENTAL
Intervention: Feeding assistance intervention (twice per day, 5 days per week for 24 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 76
Study: 17133204

Group type: EXPERIMENTAL
Intervention: DAART-Plus (colocated medical, case management, and referral to substance abuse services)
Number of subjects: 72

Group type: COMPARATOR
Intervention: DAART (self-administered therapy)
Number of subjects: 72
Study: 12649925

Group type: EXPERIMENTAL
Intervention: ACE‐I(+) group (n = 74)
Number of subjects: 246

Group type: COMPARATOR
Intervention: ACE‐I(‐) group (n = 172)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: ACE‐I(+) group
Number of subjects: 246

Group type: COMPARATOR
Intervention: ACE‐I(‐) group
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: ACE‐I(+) group (among 104 patients with Paf for < 3 months)
Number of subjects: 246

Group type: COMPARATOR
Intervention: ACE‐I(‐) group (among 104 patients with Paf for < 3 months)
Number of subjects: 246
Study: 10890645

Group type: EXPERIMENTAL
Intervention: Volume Assist (VA) at 8 cm H2O/L and 12 cm H2O/L
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV) at 10 cm H2O and 15 cm H2O
Number of subjects: 15
Study: 8684741

Group type: EXPERIMENTAL
Intervention: Concentrated oxytocin infusion plus 10-mg PGE2 vaginal suppository every 6 hours
Number of subjects: 154

Group type: COMPARATOR
Intervention: 20-mg PGE2 vaginal suppository every 4 hours
Number of subjects: 154
Study: 2032371

Group type: EXPERIMENTAL
Intervention: Psychotherapy sessions with a clinical psychologist, including discussions and relaxation techniques.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Matched control group (not specified what intervention they received).
Number of subjects: 2
Study: 6404472

Group type: EXPERIMENTAL
Intervention: Photocoagulation
Number of subjects: 268

Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 268
Study: 30472302

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride with lidocaine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine and Bupivacaine hydrochloride with lidocaine
Number of subjects: 57
Study: 30072176

Group type: EXPERIMENTAL
Intervention: Comprehensive Rehabilitation Training (CRT)
Number of subjects: 168
Study: 27751212

Group type: EXPERIMENTAL
Intervention: Moderate-severe PIVH (grades III and IV)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Mild PIVH (grades I and II)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (gestational age-matched normal preterm without ICH)
Number of subjects: 56
Study: 24660645

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment (laser simulation)
Number of subjects: 20
Study: 22345050

Group type: EXPERIMENTAL
Intervention: Test mirtazapine 30 mg single-dose formulation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 31
Study: 20412743

Group type: EXPERIMENTAL
Intervention: Cholesterol metabolism modulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential cholesterol modulators (e.g., ATP‐binding cassette transporter A1, LDL receptor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracellular cholesterol accumulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different lipoprotein classes
Number of subjects: 0
Study: 18052562

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg twice daily) for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 60
Study: 16135679

Group type: EXPERIMENTAL
Intervention: Moderate dose inhaled corticosteroids (fluticasone propionate 200 mug/day) plus salmeterol
Number of subjects: 4576

Group type: COMPARATOR
Intervention: Higher doses of inhaled corticosteroids (ICS)
Number of subjects: 4576

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 4576
Study: 12431824

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with gemcitabine/cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery plus induction gemcitabine/cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 10598596

Group type: COMPARATOR
Intervention: 1.5 l lactated Ringer's solution (LR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.5 l hydroxyethylstarch solution, 6% (0.5 l HES)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1.0 l hydroxyethylstarch solution, 6% (1.0 l HES)
Number of subjects: 36
Study: 8949271

Group type: EXPERIMENTAL
Intervention: Totally pre peritoneal (TPP) laparoscopic surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stoppa procedure (open)
Number of subjects: 100
Study: 1747702

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 7044351

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2% epinephrine hydrochloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.5% timolol maleate and 2% epinephrine hydrochloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2% epinephrine hydrochloride and 0.5% timolol maleate
Number of subjects: 32
Study: 30885778

Group type: EXPERIMENTAL
Intervention: Clip closure
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control (no closure)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Clip closure (proximal large polyp)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control (proximal large polyp)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Clip closure (distal large polyp)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control (distal large polyp)
Number of subjects: 919
Study: 28159357

Group type: EXPERIMENTAL
Intervention: Training group (N = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Validation group (N = 30)
Number of subjects: 61
Study: 25398660

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.15 % and vitamin B12 eye drops (n=32)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (n=29)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Patients without dry eye (n=42)
Number of subjects: 101
Study: 24226495

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 50 mg hyperbaric prilocaine 2%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bilateral spinal anesthesia with 50 mg hyperbaric prilocaine 2%
Number of subjects: 80
Study: 20967920

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 134
Study: 20014597

Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine (0.2%)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine (0.375%)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 66
Study: 17303970

Group type: EXPERIMENTAL
Intervention: MK-0703 12.5 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: MK-0703 50 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: MK-0703 100 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 15566375

Group type: EXPERIMENTAL
Intervention: Exemplars used in inferential prediction task after classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemplars with multiple uses in feature listing
Number of subjects: 0
Study: 11097697

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (75 mg/kg, maximum 2.5 g)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 54

Group type: COMPARATOR
Intervention: Magnesium sulfate and Placebo
Number of subjects: 54
Study: 9185026

Group type: EXPERIMENTAL
Intervention: Predictors (patients who believed they could tell when their BP was up)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Predictors
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-predictors
Number of subjects: 102
Study: 1587971

Group type: EXPERIMENTAL
Intervention: Naloxone 100 micrograms/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3835497

Group type: EXPERIMENTAL
Intervention: Piracetam (800‐6,400 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Piracetam-lecithin (4,800 mg and 25 g, respectively)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 2895689

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atracurium and Vecuronium
Number of subjects: 40
Study: 31626219

Group type: EXPERIMENTAL
Intervention: Aripiprazole at a dose of up to 20 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quetiapine at a dose of up to 600 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Haloperidol at a dose of up to 30 mg/day
Number of subjects: 90
Study: 28971849

Group type: EXPERIMENTAL
Intervention: Consumer-behavior intervention (enhanced online ordering system)
Number of subjects: 2714

Group type: COMPARATOR
Intervention: Control (standard online ordering only)
Number of subjects: 2714
Study: 25536101

Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) for 9 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 150
Study: 23238778

Group type: EXPERIMENTAL
Intervention: Mosapride (5 mg, 3/day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Lansoprazole (15 mg, 1/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (without medication)
Number of subjects: 119
Study: 21560152

Group type: EXPERIMENTAL
Intervention: Intravesical injections of 100 U of onabotulinumtoxinA into bladder body
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravesical injections of 100 U of onabotulinumtoxinA into bladder body/trigone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravesical injections of 100 U of onabotulinumtoxinA into bladder base/trigone
Number of subjects: 105

Group type: COMPARATOR
Intervention: All groups (bladder body, bladder body/trigone, bladder base/trigone)
Number of subjects: 105
Study: 18469650

Group type: EXPERIMENTAL
Intervention: Titanium alloy pins (Ti6Al4V)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stainless steel pins (Ss)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (Ti6Al4V and Ss)
Number of subjects: 80
Study: 16507847

Group type: EXPERIMENTAL
Intervention: Sputum strategy (SS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Clinical strategy (CS)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 117
Study: 12943937

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Late Partial Sleep Deprivation (LPSD)
Number of subjects: 39
Study: 11087303

Group type: EXPERIMENTAL
Intervention: Exercises to increase the force of the diagonal trunk muscle systems
Number of subjects: 44

Group type: COMPARATOR
Intervention: Training of the longitudinal trunk muscle systems
Number of subjects: 44

Group type: COMPARATOR
Intervention: Instructions to refrain from exercises
Number of subjects: 44
Study: 8659732

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 30
Study: 1357450

Group type: EXPERIMENTAL
Intervention: Revascularisation (angioplasty or coronary bypass surgery)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Medical treatment (calcium-channel-blocking drug plus aspirin)
Number of subjects: 26
Study: 4013624

Group type: EXPERIMENTAL
Intervention: Droperidol (0.014 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 100
Study: 29985942

Group type: EXPERIMENTAL
Intervention: Blood-derived CD4+ T cells
Number of subjects: 0
Study: 27926448

Group type: EXPERIMENTAL
Intervention: Competition condition
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Rematch competitions
Number of subjects: 93

Group type: COMPARATOR
Intervention: Noncompetition control conditions
Number of subjects: 93
Study: 24671721

Group type: EXPERIMENTAL
Intervention: Hypercapnic ventilation (tcPCO2 50-60 mmHg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Normocapnic ventilation (tcPCO2 35-45 mmHg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normocapnic ELBW infants
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hypercapnic ELBW infants
Number of subjects: 22
Study: 23213992

Group type: EXPERIMENTAL
Intervention: Chuzhen therapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 153
Study: 20931060

Group type: EXPERIMENTAL
Intervention: Zinc supplementation plus oral rehydration salts (ORS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral rehydration salts (ORS)
Number of subjects: 0
Study: 18816596

Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg administered intravenously intraoperatively (Arm A)
Number of subjects: 196

Group type: COMPARATOR
Intervention: No steroids (Arm B)
Number of subjects: 196
Study: 15819344

Group type: EXPERIMENTAL
Intervention: One-bottle, ethanol-based adhesive
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: One-bottle, solvent-free adhesive
Number of subjects: 57

Group type: COMPARATOR
Intervention: Two-bottle, water-based adhesive
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall retention rate for all restorations
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Marginal integrity, marginal discoloration, and air sensitivity
Number of subjects: 57
Study: 12461302

Group type: EXPERIMENTAL
Intervention: Information about the storage capabilities of a home blood pressure measuring device
Number of subjects: 48

Group type: COMPARATOR
Intervention: No information about the storage capabilities of a home blood pressure measuring device
Number of subjects: 48
Study: 11028549

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 89

Group type: COMPARATOR
Intervention: Topical antimicrobials and dressing changes
Number of subjects: 89
Study: 8761540

Group type: EXPERIMENTAL
Intervention: Low-calcium dialysate solution (LCa, 1.0 mmol/L)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard-calcium dialysate solution (SCa, 1.75 mmol/L)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) as oral phosphate binder
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide (Al(OH)3)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microgram/day per os)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bone mineral density measurements
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Skeletal x-ray films
Number of subjects: 64
Study: 1550410

Group type: EXPERIMENTAL
Intervention: Lornoxicam 6 mg once daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg twice daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lornoxicam 12 mg twice daily
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lornoxicam 12 mg daily
Number of subjects: 160
Study: 2422742

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75
Study: 29196436

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 621
Study: 27070534

Group type: EXPERIMENTAL
Intervention: Low molecular weight hyaluronic acid (LMW‐HA) injection (Hyalgan®, 500‐730 kDa), 3 injections
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-energy extracorporeal shock-wave therapy (ESWT), 4 sessions
Number of subjects: 34
Study: 26122244

Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg/kg BW, max 5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23740007

Group type: EXPERIMENTAL
Intervention: Miltefosine (50 mg three times per day for 28 days)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Thermotherapy (Thermomed® application of 50 °C for 30 seconds over the lesion and surrounding area)
Number of subjects: 294
Study: 21079465

Group type: EXPERIMENTAL
Intervention: Closed catheter system with a specially designed Tegaderm dressing
Number of subjects: 302

Group type: COMPARATOR
Intervention: StatLock device with a nonwinged catheter
Number of subjects: 302
Study: 18435392

Group type: EXPERIMENTAL
Intervention: One Arm Group (both vaccines in one arm)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Two Arm Group (one vaccine in each arm)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Neis Vac‐C (in Two Arm Group)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Recombivax HB (in Two Arm Group)
Number of subjects: 188
Study: 16001131

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study: 12511765

Group type: EXPERIMENTAL
Intervention: Antidepressive medication (exact dosage and duration not specified)
Number of subjects: 100
Study: 10682151

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine combination therapy
Number of subjects: 29
Study: 7815570

Group type: EXPERIMENTAL
Intervention: Technique 1 (seromuscular bowel flap tube) in 11 patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Technique 2 (full thickness bowel flap tube) in 6 patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall results for both techniques
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Seromuscular bowel flap tube
Number of subjects: 17
Study: 1682533

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 28
Study: 7027040

Group type: EXPERIMENTAL
Intervention: High-BUN group
Number of subjects: 151

Group type: COMPARATOR
Intervention: Low-BUN group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Dialysis treatment time (long or short)
Number of subjects: 151
Study: 31141424

Group type: EXPERIMENTAL
Intervention: Hip mobilization with movement (MWM) technique
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham mobilization
Number of subjects: 56
Study: 30229461

Group type: EXPERIMENTAL
Intervention: DBT‐ST plus TAU
Number of subjects: 95

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 95
Study: 28495391

Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent (ECA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Patient education sheets plus a meditation CD/MP3
Number of subjects: 61
Study: 25716637

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (50,000 IU weekly)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 24016557

Group type: EXPERIMENTAL
Intervention: Type A treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Type B treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Type C treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Type D treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Combined treatment (Glucocorticoid)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Overall treatment results
Number of subjects: 1024
Study: 20608918

Group type: EXPERIMENTAL
Intervention: Grass AIT (Grazax, Phleum pratense, 75,000 SQ-T/2,800 BAU)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634